Universal Ibogaine Inc
XTSX:IBO
Universal Ibogaine Inc
Research & Development
Universal Ibogaine Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Universal Ibogaine Inc
XTSX:IBO
|
Research & Development
-91.8k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Universal Ibogaine Inc
Glance View
Universal Ibogaine, Inc. develops ibogaine based drug franchise to treat addiction and related mental health issues. The company is headquartered in Calgary, Alberta. The company went IPO on 2017-06-21. The firm is focused on developing medicines and building a network of holistic recovery clinics for the treatment of addictions. The company treats addictions primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. Its focuses on developing ibogaine for the treatment of opioid use disorders. Ibogaine is a neuroactive compound, which is derived from various plants. Ibogaine helps to repair damaged brain tissues of the patients and helps them to recover and rebuild their lives.
See Also
What is Universal Ibogaine Inc's Research & Development?
Research & Development
-91.8k
Based on the financial report for Jul 31, 2024, Universal Ibogaine Inc's Research & Development amounts to -91.8k .
What is Universal Ibogaine Inc's Research & Development growth rate?
Research & Development CAGR 1Y
-898%
Over the last year, the Research & Development growth was -898%.
